Evonik has officially broken ground on a major biotechnology expansion project at its historic Fermas site in Slovenská Ľupča, Slovakia. This milestone marks the formal commencement of an approximately €80 million (US$92.78 million) investment designed to significantly bolster the company’s contract manufacturing capabilities for complex pharmaceutical drug substances.
The project is set to introduce state-of-the-art downstream fermentation technology to the facility, providing a critical boost to the site’s capacity for both the development and large-scale manufacturing of high-value pharmaceutical intermediates. By integrating these advanced processes, Evonik aims to provide its partners with greater scalability and precision, addressing the increasing demand for complex molecular structures in modern medicine.
This expansion represents the latest chapter in a long-standing history of innovation at the Fermas site. Since its founding in 1992, the location has evolved from its initial focus on amino acid production into a strategic, multi-faceted biotechnology manufacturing hub. Today, it serves a diverse portfolio of sectors, including the pharmaceutical, personal care, nutrition, and specialty chemical industries.
Industry analysts note that this project arrives at a pivotal time for the pharmaceutical sector. As drug development shifts toward more sophisticated biological entities, biotechnology has moved to the forefront of manufacturing strategy. These advanced fermentation processes are not only essential for creating intricate molecules but are also lauded for their environmental benefits. By utilizing biological pathways, manufacturers can significantly reduce their reliance on traditional organic solvents and minimize process-related waste, moving the pharmaceutical industry toward a more sustainable production model.
Lauren Kjeldsen, a member of the Management Board and Chief Operating Officer at Custom Solutions for Evonik, emphasized that the investment is a direct reflection of the company’s forward-looking strategy. “It fits our strategy to expand our biotechnology platform, supporting customers with innovative, scalable, and sustainable manufacturing solutions,” Kjeldsen stated. “Biotechnology demonstrates how economic growth and sustainability can go hand in hand.”
The company’s commitment to sustainable operations is already evident at the Slovakian facility, which currently operates on 100% green electricity and utilizes certified renewable raw materials for key processes.
Miroslav Havlik, General Manager of Evonik Fermas, expressed strong confidence in the expansion’s potential for the region. The project is projected to be completed by 2028 and is expected to create approximately 50 new highly skilled jobs. This infusion of talent and technology will solidify the Fermas site’s status as a cornerstone of Evonik’s global biotechnology infrastructure. As the pharmaceutical industry continues to navigate the complexities of modern drug production, Evonik’s significant capital commitment in Slovakia signals a clear belief in the long-term viability and necessity of bio-based manufacturing solutions.
Disclaimer: This content is auto-generated for informational purposes only.
Source: Read Original News
